



vaccines

Dear Colleagues!

You are heartily invited to participate in online international conference **VACCINES AND VACCINATION DURING AND POST COVID PANDEMICS “VAC&VAC 2022” December 7-9, 2022**. Conference will be held online in Zoom on the platform of Riga Stradins University, Riga, Latvia.

Conference will cover the progress in the development of vaccines achieved since the start of SARS-CoV-2 pandemics. It will have sessions on COVID-19, HPV and cancer vaccines, progress in the development of vaccines against HIV-1 and other new and re-emerging microbial threats, and populational aspects of vaccination. Topics will be presented by the renown scientists from USA, South Korea, China, South Africa, Italy, Sweden, Denmark, Holland and Latvia. Program of invited lectures is available at <https://www.rsu.lv/en/vac-vac-2022>.

Registration for the conference is free. **To register, please, e-mail to the conference management at VACandVAC2022@gmail.com**. In the email, please, provide your full name, affiliation, position, email and mobile phone number, and year of birth. Participants under 36 years of age are eligible to participate in the contest of studies done by the early career researchers. **Registration opens on October 24, 2022 and closes December 5, 2022.**

To participate in the conference with presentation, you need to submit an abstract. Abstracts can be submitted at the time of registration. Information about abstract format, submission and processing can be viewed here <https://www.rsu.lv/en/vac-vac-2022>. **Deadline to submit an abstract is November 24, 2022.** Decision on acceptance and presentation form will be communicated to registered participants by email by November 28, 2022 the latest.

Registered participants presenting their studies at the conference will be invited to submit them as manuscripts to the special issue of VACCINES [Vaccines | Special Issue: Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines \(mdpi.com\)](https://www.mdpi.com/journal/vaccines/special_issue/pandemics). VACCINES (mdpi) offers 20% reduction of processing charges.

Program Committee organizes a contest for the best presentations of early career researcher. Three winners will get monetary awards from VACCINES (mdpi). Two best papers of the early career researchers will get free publication vouchers!

Welcome to join us on the Conference!

Program and Organizing Committees of VAC&VAC2022



vaccines

VACCINES AND VACCINATION DURING AND POST COVID PANDEMICS “VAC&VAC 2022”

Online, December 7-9, 2022

Web Platform of the Riga Stradins University, Riga, Latvia
Co-budged by the International Society for Vaccines ISV

Co-Chairs:

Franco M. Buonaguro, Experimental Oncology Department, National Cancer Institute “Fond Pascale”, Naples, Italy, and

Maria Isaguliantis (Issagouliantis), Department of Research, Riga Stradins University, Riga, Latvia, and Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Partners:

Riga Stradins University, Riga, Latvia, with support of LZP project 2021/1-0484.

National Cancer Institute “Fond Pascale”, Naples, Italy

International Society for Vaccines, www.isv.org

VACCINES <https://www.mdpi.com/journal/vaccines>

No registration fees! Registration and abstract submission can be done by email to conference manager VACandVAC@gmail.com.

Program is given below. All information on the conference program, registration, abstract submission, with updates is published on <https://www.rsu.lv/en/vac-vac-2022>.

Registered participants are invited to present their studies in the special issue of VACCINES (will be released early October 2022). [Vaccines | Special Issue: Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines \(mdpi.com\)](#). As conference partner, VACCINES will give awards to three winners of the contest of early career researchers for the best research presentation. Two best papers of the early career researchers will get free publication vouchers, and the rest, a 20% reduction of processing charges!

The banner features the Vaccines journal logo on the left, an Impact Factor badge (4.961) and PubMed indexing badge on the right, and the title of the special issue in the center. Below the title, it lists the guest editors and the submission deadline.

vaccines
an Open Access Journal by MDPI

IMPACT FACTOR 4.961
Indexed in PubMed

Pandemics - Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines

Guest Editors
Dr. Maria G. Isaguliantis
Co-Guest Editors
Prof. Dr. Felicity Jane Burt, Dr. Ilya Gordeychuk

Deadline
15 March 2023

Special Issue
Invitation to submit

[mdpi.com/si/129976](https://www.mdpi.com/si/129976)

PROGRAM

December 7, 2022

14.00 – 16.00 SESSION I COVID-19 PANDEMICS & VACCINES

Chair:

PLENARY LECTURE Ranjit Ray (Edward A. Doisy Research Center, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University, Saint Louis, USA) SARS-CO-2 AND INFLAMMATION **CONFIRMED**

Margaret Liu (Protherimmune, University of California, San Francisco, USA; liu@protherimmune.com) DEVELOPMENT OF DNA VACCINES AGAINST SARS-COV-2, AN OVERVIEW **CONFIRMED**.

Manki Song (International Vaccine Institute, Seoul, Republic of Korea; mksong@ivi.int) DEVELOPMENT OF VIRAL VACCINES ON VESICULAR STOMATITIS VIRUS (VSV) PLATFORM, PROGRESS FOR SARS-CoV-2 **CONFIRMED**

Ed Rybicki (University of Cape Town, Cape Town, South Africa; ed.rybicki@uct.ac.za) THE POTENTIAL OF PLANTS AS RAPID-RESPONSE EXPRESSION PLATFORMS FOR PANDEMIC RESPONSE. Host plant engineering in the context of rapid vaccine development, with examples of SARS-CoV-2 and other (re)emerging viral threats. **CONFIRMED**

Uldis Vegners (Riga Stradins University, Riga, Latvia; Uldis.Vegners@rsu.lv) HESITANT BODIES: PHENOMENOLOGICAL ANALYSIS OF THE EMBODIED EXPERIENCE OF COVID-19 VACCINE HESITANCY. **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

16.30 – 18.30 SESSION II. DEVELOPMENT OF HIV VACCINES

Chair:

PLENARY LECTURE Jean Louis Excler (International Vaccine Institute, Seoul, Republic of Korea; JeanLouis.Excler@ivi.int) CURRENT APPROACHES TO HIV VACCINE DEVELOPMENT – DO WE GET A BOOST? (title tentative) **CONFIRMED**

Paolo Palma (Academic Department of Pediatrics, Children Hospital/Ospedale-Pediatico-Bambino-Gesu, Roma, Italy; paolo.palma@opbg.net; paolo.palma@uniroma2.it). THERAPEUTIC HIV-1 VACCINES FOR HIV-1 INFECTED CHILDREN, update from update from the HURRICAN study **CONFIRMED**

Charlotta Nilsson (The Public Health Agency of Sweden, and Department of Medicine, Karolinska Institutet, Stockholm, Sweden) HIV-1 VACCINE TRIALS IN SUB SAHARAN AFRICA **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

19:00-20.00 POSTER SESSION

PROGRAM

December 8, 2022

12.00 – 13.30 CAPACITY BUILDING WORKSHOP ON RESEARCH IMPACT AND IMPLEMENTATION

Dr Charlotta Lindquist (External Engagement Office, Karolinska Institutet, Stockholm, Sweden; charlotta.lindquist@ki.se) **WAYS TO ACHIEVE HIGH IMPACT IN ACADEMIC RESEARCH**

CONFIRMED

Dr Patrik Blomquist (Karolinska Institutet Innovation AB, Stockholm, Sweden, patrik.blomquist@kiinnovations.se) **COMMERCIAL IMPLEMENTATION OF RESEARCH FINDINGS**

CONFIRMED

Dr Ying Zhao (Grants Office, Karolinska Institutet, Stockholm, Sweden; ying.zhao@ki.se) GRANT WRITING, ABC OF PREPARING SUCCESSFUL GRANT APPLICATIONS **CONFIRMED**

Break

14.00 – 16.30 SESSION III. HPV INFECTION & HPV VACCINATION

Chair:

PLENARY LECTURE Tina Dalianis (Institute for Oncology Pathology, Karolinska Institutet, Stockholm, Sweden; tina.dalianis@ki.se) **THE POPULATION-LEVEL IMPACT AND HERD EFFECTS OF THE INTRODUCTION OF HPV VACCINATION** **CONFIRMED**

Anda Kivite-Urtane (Riga Stradins University, Riga, Latvia; anda.kivite-urtane@rsu.lv). **KNOWLEDGE AND ATTITUDE TO HPV VACCINATION AMONG WOMEN IN LATVIA.** Main topic coming out from our primary data study is: Prevalence of high risk HPV types in Latvia and associated factors. Secondary topic - whether women are taking part in CC screening and what are the associated factors **CONFIRMED**

Anna-Lise Williamson (University of Cape Town, Cape Town, South Africa, anna-lise.williamson@uct.ac.za) **HPV AND HPV VACCINATION IN PEOPLE LIVING WITH HIV-1.** Features of HPV infection in people living with HIV. Specifically interesting would be to address HPV genotypes in HIV+ and HIV- communities and potential effects of differential prevalence on the protectivity of prophylactic HPV vaccination. **CONFIRMED**

Sona Chowdhury (University of California, San Francisco, USA; sona.chowdhury@ucsf.edu) **STRATEGIES TO PREVENT HPV ASSOCIATED CANCER. HPV OR LIQUID CYTOLOGY SCREENING – WHAT ANCHOR STUDY TELLS US?** The clinical trial of people living with HIV ANCHOR has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions (HSIL) reduces the chances to develop anal cancer by 57%. **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

17.00 – 19.00 SESSION IV: CANCER VACCINES

Chair:

PLENARY LECTURE Margaret Liu (Protherimmune, University of California, San Francisco, USA; liu@protherimmune.com) **CANCER VACCINES OF TODAY - DO WE GET AHEAD/HOW DO WE GET**

AHEAD WITH NEW VACCINE VEHICLES BORN IN PANDEMICS? Historical vision on the development of DNA and RNA (genetic) vaccines against cancer in pre-COVID era. A lot has changed for this type of vaccines after they had been applied for SARS-CoV-2. The idea is to come back to the subject and review it again. **CONFIRMED**

Luigi Buonaguro (National Cancer Institute “Fond Pascale”, Naples, Italy; l.buonaguro@istitutotumori.na.it) CANCER VACCINE DEVELOPMENT IN LIVER CANCER **CONFIRMED**

Joel Palefsky (University of California, San Francisco, USA; joel.palefsky@ucsf.edu) THERAPEUTIC VACCINES TO TREAT CHRONIC HPV INFECTION AND ASSOCIATED CANCER **CONFIRMED**

Joon Haeng Rhee (Department of Microbiology and Immunology, Chonnam National University, Gwangju, South Korea; happypa1101@gmail.com) RECOMBINANT PROTEIN HPV VACCINE COMBINING E7, TLR4 ADJUVANT AND DC TARGETING **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

PROGRAM December 9, 2022

14.00 – 16.00 SESSION V. FACING NEW AND RE-EMERGING THREATS

Chair:

PLENARY LECTURE Genoveffa Franchini (Center for Vaccine Research, National Cancer Institute, Bethesda, USA; franchig@mail.nih.gov) NEW VACCINES AGAINST HTLV-1 (title tentative) **CONFIRMED**

Felicity J Burt (Division of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa; burtfj@ufs.ac.za) ADVANCES IN VACCINE DEVELOPMENT FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS (preliminary) **CONFIRMED**

Tatjana Tallo (Folkhälsomyndighet, Solna, Sweden; tatjana.tallo@folkhalsomyndigheten.se) DO WE NEED HEPATITIS B VACCINE? (preliminary title) **CONFIRMED**

Anke LW Huckriede (Department of Medical Microbiology & Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; a.l.w.huckriede@umcg.nl) A HUMAN BLOOD CELL-BASED IN VITRO SYSTEM FOR ASSESSING VACCINE QUALITY AND ELUCIDATING VACCINE-INDUCED IMMUNE MECHANISMS **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

16.30 – 18.30 SESSION VI. NOVEL VACCINE VEHICLES, ADJUVANTS AND CARRIERS

PLENARY LECTURE Dennis Christensen (Croda Pharma, Frederikssund, Denmark; Dennis.Christensen@croda.com) ADJUVANTS – THE TOOL TO OBTAIN THE REQUIRED IMMUNE RESPONSES IN PROPHYLACTIC AND THERAPEUTIC VACCINATION **CONFIRMED**

Anna Zajakina (Latvian Biomedical Research and Study Centre, Riga, Latvia; anna.zajakina@gmail.com)
THERAPEUTIC MODULATION OF TUMOR MICROENVIRONMENT WITH RECOMBINANT VIRAL
VECTORS **CONFIRMED**

Yufei Xia (State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese
Academy of Sciences, Beijing, PR China; yfxia@ipe.ac.cn) ENGINEERING PICKERING EMULSION AS VACCINE
DELIVERY SYSTEM **CONFIRMED**

Jorma Hinkula (Linköping University, Linköping, Sweden; jorma.hinkula@lu.se) GOLD NANOPARTICLE-
BASED ADIVANTS FOR VACCINES AGAINST INFECTIOUS DISEASES **CONFIRMED**

Orals selected by program committee on the basis of submitted abstracts.

Break

19.00 – 20.00 WORKSHOP ON RESEARCH FUNDING

*Joint effort of the Latvian Council of Science of Latvia, Ministry of Education and Science of the Republic of
Latvia and Research Support Office, Karolinska Institutet, Stockholm Sweden.*

Dr Inga Sirante, Latvian Council of Science, and University of Latvia, Riga, Latvia **NEGOTIATED**

Dr Uldis Berkis, Department of Higher Education, Science and Innovation, Ministry of Education and
Science of the Republic of Latvia, and Riga Stradins University, Riga, Latvia **CONFIRMED**

Discussion

**20.00 Program committee announce three awards for the best early career researcher presentations and
two presentations rewarded with vouchers to publish in VACCINES.**

20.30 CLOSING

Abstract submission process

To participate in the conference **VACCINES AND VACCINATION DURING AND POST COVID PANDEMICS “VAC&VAC 2022”** with presentation, you need to submit an abstract.

Abstracts can be submitted at the time of registration, or later. **Deadline for abstract submission is November 24, 2022.**

Please, email your abstract as Word file (format is given below), indicating the desired session and form of presentation (oral, poster). Oral presentations will be given slots of 10 to 20 min in each session, following the invited talks. Poster session will be organized in the form of 5 min orals with presentation of materials as ppt with maximum 5 slides, or PDF file.

Submissions are open in the sessions: (1) Covid-19 pandemics & vaccines; (2) Development of HIV-1 vaccines; (3) HPV infection & HPV vaccination; (4) Cancer vaccines; (5) Facing new and re-emerging threats; (6) Novel vaccine vehicles, adjuvants and carriers.

Abstract format

Regular abstracts

Abstracts should be typed in Times New Roman, size 11, one line spacing. Length of the text (without title, authors' names, affiliations) is limited to 500 words.

Abstract should contain the following components:

- Title (not more than 150 characters with spaces);
- Authors (surname, given name), indicate the corresponding author;
- Affiliations for all authors;
- Background: a concise statement of the issue under investigation or a hypothesis;
- Materials & Methods: the experimental methods used (including the statistical analyses employed);
- Results: specific findings;
- Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions);
- Acknowledgements, references to publications (max 5)
- The maximum size of the abstract file is 2 megabytes.

Abstract can contain one figure with legend, or one table in good resolution for direct reproduction. Max volume of the abstract with illustration should not exceed two pages.

Abstracts of invited review lectures

Abstracts should be typed in Times New Roman, size 11, 1 line spacing and contain the following components:

- Title (is not more than 150 characters with spaces);
- Authors (surname, given name), indicate the corresponding author;
- Affiliations for all authors;
- Background: describe the importance of the revised field of research;
- Aim(s): subject of the review;
- Topics overviewed: short description of the overviewed topics; own findings of the author in this context;
- Conclusions: resume of the progressed achieved so far and perspectives for the development.
- Acknowledgements, references to publications (max 5).

Abstract evaluation & publication

All submitted abstracts will be reviewed by the Program Committee. **Decision on the acceptance and presentation form will be communicated to registered participants by email, the latest on November 28, 2022.**

Accepted abstracts will be compiled into Abstract book which will be sent by email to all participants. Organizing committee negotiates possibility to publish abstract book with no additional charges to conference participants, and to publish conference report reviewing all presented studies in one of MDPI journals.